NQPC-05 BEVACIZUMAB AFTER PROGRESSION OF GLIOBLASTOMA PROLONGS PATIENT’S LIVING TIME AT HOME IN THE LAST 90 DAYS

Bevacizumab (Bev) is currently available for recurrent glioblastoma to improve a patient’s quality of life (QoL). To maintain a patient’s daily life activity, Bev is sometimes continued beyond radiographical progression until neurological deteriorations. However, the benefit of continuous use of Bev...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsutani, Tomoo, Hirono, Seiichiro, Iwadate, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213194/
http://dx.doi.org/10.1093/noajnl/vdz039.136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213194/
http://dx.doi.org/10.1093/noajnl/vdz039.136

Ejemplares similares